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Case presentation
A 64-year-old Mexican-American woman was referred to the nephro-
logy clinic at UCLA 3.5 years ago, having been followed by an internist
for the previous 8 months because of chronic renal failure. Fourteen
years ago, the patient was found to have mild hypertension. Four years
later, the serum creatinine was 2.4 mg/dl and she had 3 + proteinuria. A
renal biopsy was not performed; the diagnosis was presumed to be
chronic glomerulonephritis. The patient's history also suggested that
she might have gout. She was followed by her referring physician, who
documented that her blood pressure was under good control until one
month before the detection of advancing renal failure. At that time,
blood pressure was 190/98 mm Hg standing and 198/94 mm Hg supine.
Hydralazine, 25 mg twice daily, was added to her previous antihyper-
tensive medications, which were propranolol, 80 mg three times daily,
and hydrochlorothiazide, 50 mg daily. Serum creatinine was 3.6 mg/dl;
urinalysis revealed 2 + protein, 5 to 10 red blood cells/high-power field;
and 5 to 10 white blood cells and numerous granular casts/high-power
field. Repeated blood pressure measurements over the next few months
ranged from 170/72 mm Hg to 180/90 mm Hg. One month prior to
referral to UCLA, creatinine clearance was 10 mI/mm; serum creati-
nine, 5.1 mgldl; and proteinuria, 2.2 g124 hours.
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When the patient was seen at UCLA, she was taking propranolol, 80
mg four times daily; furosemide, 40 mg/day; minoxidil, 2.5 mg/day;
allopurinol, 100 mg/day; ferrous sulfate, 325 mg three times daily; and
folic acid, I mg/day. On examination she was a pale woman with hair
over the back of the arms and on the sides of the face. Blood pressure
was 190/100 mm Hg supine and 190/100 mm Hg standing; the pulse was
88 beats/mm and regular. Optic fundi showed grade I-I! hypertensive
retinopathy. Cardiac apex beat was localized to the 5th intercostal
space, just inside the anterior axillary line. An S3 was heard. The lungs
were clear. There was no jugular venous distention, hepatomegaly, or
edema. Peripheral pulses were intact and symmetrical. Central nervous
system examination was normal. Urinalysis showed 2 + protein, and 5
to 10 white blood cells, 5 to 10 red blood cells, and numerous granular
casts/high-power field. Minoxidil was increased to 2.5 mg twice daily,
and both furosemide and propranolol were continued. The patient was
instructed to reduce her protein intake by eliminating meat, fish, eggs,
and milk from her diet.
Over a 3-year period, blood pressure was maintained in the range of
150—180/85—95 mm Hg. Dietary compliance was determined by history
only and was not rigorously controlled. Serum creatinine determina-
tions, performed every 2 to 3 months, fluctuated between 5.0 and 5.9
mg/dl over the 3-year period of followup. The most recent findings are:
serum creatinine, 6.4 mg/dl; creatinine clearance, 6.4 mI/mm; BUN, 78
mg/dl; and urine protein excretion, 1 g124 hrs. Protein intake, calculated
from the 24-hour urea excretion rate plus an estimated excretion of
non-urea nitrogen of 2.5 g/day, has been approximately 40 g/day. The
patient continues to function normally and to feel well and has not
developed any symptoms or signs that suggest uremia,
Discussion
DR. LEON G. FINE (Chief, Division of Nephrology, Center
for the Health Sciences, and Professor of Medicine, UCLA
School of Medicine, Los Angeles, California): We are currently
in the midst of a flurry of investigational activity that has raised
the hope that the downhill course of many human chronic renal
diseases may be retarded or perhaps even arrested. Much of
this optimism is based on the results of studies in experimental
animals. While such studies clearly have advanced our under-
standing of the pathophysiologic mechanisms of nephron de-
struction, it is not at all clear that extrapolations safely can be
made to human disease. Furthermore, even where such extrap-
olations appear to be appropriate based on our understanding of
the physiology of the human kidney, there are quantitative
considerations that might make the disease process in humans
either more or less treatable than it is in the animal models.
My discussion will first compare animal models of experi-
mental renal diseases with renal diseases in humans. Then I will
consider the factors that contribute to the progressive nature of
these diseases, emphasizing the applicability of proposed patho-
physiologic processes to human disease. I will appraise current
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Table 1. Long-term effects of reduction of renal mass on glomerular
function in different species
Species Model Outcome References
Rat
Rabbit
Dog
Human
Uninephrectomy + contralateral
subtotal nephrectomy
Uninephrectomy + contralateral
subtotal nephrectomy
Uninephrectomy ÷ contralateral
subtotal nephrectomy
Uninephrectomy
Progressive
reduction
of GFR
No reduction
of GFR
No reduction
of GFR
No reduction
of GFR
1, 2, 3, 15,
29, 32,
33
8
10, 16
17, 18, 19
approaches to therapy and will evaluate the efficacy of these
approaches in human renal failure. Finally, I will propose a
hypothetical framework for an approach for predicting the
patients response to therapy.
Natural history of experimental and human renal disease
Subtotal renal ablation. Subtotal nephrectomy, including
unilateral nephrectomy, leads to changes in the function of the
remaining nephrons in rats [1—3], rabbits 14—8], dogs [9—10], and
humans [11—13]. These changes include an immediate elevation
in single-nephron glomerular filtration rate (that is, hyperfiltra-
tion), hypertrophy of all parts of the nephron, and adaptations
in tubular reabsorptive and secretory processes. As early as
1932, Chanutin and Ferris observed that removal of three-
quarters of the total renal mass in the rat led to a slowly
progressive deterioration in the function of the remaining neph-
rons, with progressive azotemia and glomerular sclerosis [1].
This glomerular lesion of the remnant kidney is associated with
significant proteinuria, which is now known to be due to loss of
charge-selectivity and size-selectivity of the glomerular capil-
lary wall [14]. Of interest is the fact that, in rats on a high-
protein diet, even unilateral nephrectomy leads to significant
proteinuria and glomerular sclerosis after 8 months, without a
decline in GFR [15]. This observation is important, because
reliable information in humans is confined to the effects of
uninephrectomy, as I will discuss later.
Does this sclerotic glomerular lesion, which is so consistently
observed in rats, also occur in other species, especially in
humans? The literature suggests that it does not. Table I
compares the long-term effects of reduction of renal mass in
different species. Subtotal nephrectomy in the rabbit leads to a
progressive interstitial fibrotic reaction in the remaining renal
tissue [4, 8] but does not compromise glomerular structure over
a 6-month period [8]. There are few long-term studies in dogs
with remnant kidneys, but in two studies extending for 2 and 4
years respectively (a long time in the life of a dog!), the GFR did
not deteriorate with time irrespective of the level of protein
intake [10, 16]. Limited studies in humans likewise have failed
to show that ablation of renal mass compromises the function of
the remaining nephrons. Most of the evidence in this regard is
obtained in long-term followup of donors of kidneys for trans-
plantation. Although there appears to be a slightly increased
incidence of mild proteinuria and mild hypertension in these
individuals [17], followup periods of more than 10 years fail to
reveal functional deterioration, even in the presence of hyper-
tension [18]. Although the levels of proteinuria and blood
pressure in these donors are usually compared to values in age-,
sex-, and race-matched controls, the possibility must be con-
sidered that this population, being related to patients with renal
disease and hypertension, might be genetically predisposed to
hypertension with associated mild proteinuria, and that the
higher incidence of these findings is unrelated to the loss of a
kidney. The fact that the magnitude of proteinuria does not
correlate with duration of followup [18] suggests that a progres-
sive, acquired glomerular injury is not the cause of the protein-
uria. What is needed for future studies is a comparably matched
control group of siblings of transplant recipients who have not
donated a kidney.
Robitaille et al recently reported on a long-term followup of
32 patients who had undergone unilateral nephrectomy in
childhood (mean age 2.1 years) for tumor, dysplasia, hydrone-
phrosis, or trauma [19]. No evidence for an increased incidence
of impaired renal function or hypertension could be found after
a mean followup period of 23 years when compared with 24
healthy control subjects of similar age.
Thus, no convincing evidence exists to indicate that progres-
sive renal injury follows reduction of renal mass by 50% in
humans, but whether progressive damage occurs in patients
with greater degrees of renal ablation is not known. In anec-
dotal reports in which progressive disease appears to follow
extensive renal ablation, it is important to exclude the role of
untreated systemic hypertension (perhaps mediated by ische-
mia in the remnant kidney) as a causal factor. Although
deterioration of renal function has been found with unilateral
renal agenesis, bilateral cortical necrosis, and vesicoureteral
reflux, all of which are associated with a reduction of the
nephron population [20], the same damage that mediated the
initial loss of function in these diseases might be responsible for
the subsequent downhill course of the disease.
Glomerulopathies. The progressive nature of human glomer-
ulonephritis and other glomerulopathies, particularly diabetic
glomerulosclerosis, has spawned a number of experimental
models that have been used to study mechanisms of progres-
sion.
In animal models of disease, the same hyperfiltration (that is,
an increase in single-nephron glomerular filtration rate) that
occurs in the remnant kidney occurs in rats with streptozotocin-
induced diabetes mellitus [21]. In this model the glomerular
lesion is progressive, associated with proteinuria, and aggra-
vated by unilateral nephrectomy. In contrast, the BB rat strain
with congenital diabetes mellitus also demonstrates an increase
in GFR, but in this model renal function remains stable, and the
rat does not develop proteinuria [22]. Experimental glomerulo-
nephritis is accompanied by heterogeneous nephron injury [23]
and a wide dispersion of values for single-nephron GFR (SNGFR)
[24]. Some nephrons, however, presumably escape injury; in
these, GFR increases and hypertrophy occurs. Ultimately, all
the nephrons are destroyed, including those that initially ap-
peared to be intact.
In a number of human renal diseases, an increase in GFR may
occur during the earlier phases of the disease. In nonglomerular
(tubulointerstitial) disease, a rise in SNGFR is the rule [25]. The
early stages of human juvenile-onset diabetes are associated
with a rise in GFR, which precedes the onset of microalbumin-
uria, overt proteinuria, and the ultimate fall in GFR; all these
118 Nephrology Forum: Preventing the progression of human renal disease
attend nephron destruction [26—281. Although direct measure-
ments of GFR in individual nephrons obviously are not avail-
able in humans, the observation by Oliver that some glomeruli
in human chronic glomerulonephritis are enlarged and are
attached to hypertrophied tubules [23] suggests that some
nephrons escape damage early in the process and undergo
compensatory adaptations, which include a rise in SNGFR.
Again, diffuse destruction of all nephrons characterizes the
terminal stage of human glomerulonephritis.
Table 2. Criteria required to establish that glomerular hypertension is
a common pathogenetic factor in progressive glomerular injury
1. In all species in which it occurs, sustained glomerular hypertension
should lead to progressive glomerular injury.
2. Prevention or early reversal of glomerular hypertension should
prevent or arrest, respectively, progression of glomerular injury.
3. In heterogeneous forms of glomerular injury, a direct correlation
should exist between maximum glomerular capillary pressure and
the degree of sclerosis in the same glomerulus.
Why is renal disease progressive?
Three postulates have been invoked to explain the progres-
sive nature of renal disease. These are (1) ongoing injury due to
the primary cause of the disease, (2) secondary injury to
glomeruli, either due to compensatory adaptations in unin-
volved or minimally involved glomeruli, or to intraglomerular
coagulation abnormalities, and (3) secondary injury due to
compensatory adaptations or alterations in tubular and intersti-
tial function. In certain cases it is difficult to separate glomer-
ular from tubular or interstitial abnormalities, but these three
postulates will be considered separately for the sake of clarity.
Ongoing injury due to the primary cause of the renal disease
Unfortunately, the primary cause of the injury is understood
in very few progressive, primary renal diseases. In addition, the
offending cause can be eliminated in only a small number of
disorders. Apart from infectious causes of immunologically
mediated glomerulonephritis, one example of an "idiopathic"
disease that can be arrested by removal of an identifiable cause
of the insult is anti-glomerular basement membrane (GBM)
disease. Although the primary cause of the rise in anti-GBM
antibody is unknown, removal of the offending antibody by
means of plasmapheresis may attenuate or prevent damage to
the kidney. Other examples are the prevention of renal injury in
many patients with essential hypertension by lowering the
blood pressure, and the arrest of tubulointerstitial disease by
removing an offending drug or toxin. Until the injurious agents
that initiate a variety of primary glomerulonephritides are
discovered, our efforts must be directed towards limiting sec-
ondary effects that aggravate the condition. This discussion,
therefore, will not consider pharmacologic approaches to sup-
pression of primary injury in the kidney.
Secondary injury due to glomerular capillary hypertension
The recent focus of attention on the "hyperfiltration" con-
cept of secondary renal injury is due to the appealing simplicity
of the concept and the impressive data from experimental
studies by Brenner, Hostetter, Meyer, and colleagues over the
past 5 years [15, 20, 29, 30—341. The idea that adaptations in
glomerular function could lead to progression of disease was
first proposed in 1975 by Shimamura and Morrison, who stated:
"The earlier clear demonstration of hyperfiltration in the gb-
meruli remaining after partial 5/6 nephrectomy appears to us as
the most likely basis for the alteration in gbomerular morphol-
ogy observed [21. This concept suggests that the cause of
progression of the glomerular lesion is the very compensatory
increase in SNGFR of surviving glomeruli that, if viewed
teleobogically, alleviates the reduction in total GFR caused by
the initiating injury [20]. In the rat remnant kidney [30], as well
as in stieptozotocin-induced diabetes mellitus [21], elevated
glomerular plasma flow and elevated glomerular capillary hy-
draulic pressure (the latter will be referred to as 'gbomerular
hypertension") have been observed. Because a high protein
intake increases glomerular filtration rate [29, 351 and glomer-
ular capillary pressure [29], and because reduction of protein
intake in these experimental models blunts the hyperfiltration
response and limits the extent of the gbomerular injury and
proteinuria [15], it has been suggested that some aspect of
hyperfiltration causes progression of renal disease [291.
The hyperfiltration concept has been further refined by the
demonstration that glomerular hypertension, not increased plasma
flow, leads to renal injury [31]. This conclusion comes from
observations in rats in which protein intake has been reduced
only after the renal injury has become established; in this case,
protein restriction does not affect the elevated glomerular
plasma flow, but does reduce glomerular capillary hydraulic
pressure [31]. These alterations are associated with reduced
glomerular injury and macromolecule clearance as well as with
preservation of GFR. An additional clue to the primacy of
glomerular hypertension in the pathogenesis of progressive
glomerular sclerosis is the observation that converting enzyme
inhibitors protect the rat remnant kidney [32, 33] and the kidney
of rats with streptozotocin-induced diabetes meffitus [34] against
progressive gbomerular damage. Reversal of the constrictive
effects of angiotensin II on the efferent arteriole by these agents
does not alter the elevated glomerular plasma flow and filtration
rate, but it does reduce glomerular capillary hydraulic pressure.
Recently a calcium-channel blocking agent, verapamil, also was
shown to slow the progression of disease in the rat remnant
kidney model [361. Although calcium deposition might contrib-
ute to renal injury in this model [371, it is possible that this
protection is due to a hemodynamic effect rather than to an
effect on tissue calcium accumulation.
These observations have fueled the speculation that progres-
sive renal damage in such disparate diseases as minerabocor-
ticoid-salt hypertension, radiation nephritis, nephrotoxic serum
nephritis, bilateral cortical necrosis, and unilateral renal agen-
esis is due to hyperfiltration injury [20]. Are such far-reaching
speculations justified and, even if valid in the rat, how applica-
ble are they to human glomerular disease? We can assess the
strength of the evidence favoring the broad applicability of this
concept by applying some simple "Koch-type" postulates to
the available data (as shown in Table 2). If the progression of
renal disease is due to glotnerular hypertension, the following
would be expected: (1) In previously intact nephrons as well as
in diseased nephrons, glomenilar hypertension—if sustained for
a sufficient period of time by any maneuver—should produce
progressive loss of gbomerular function. (2) Reversal of gbomer-
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ular hypertension should slow or arrest progression of glomer-
ular disease. (3) A direct correlation should exist between the
glomerular capillary pressure and the extent of glomerular
sclerosis in the same glomerulus [38].
I will now turn to an analysis of the evidence indicating that
there are sufficient deviations from these postulates to raise
doubt about the pathogenetic role of glomerular hypertension in
progressive glomerular sclerosis. I should point out first that
some of the most recent information cited here is available in
preliminary (abstract) form only and awaits definitive confirma-
tion.
Inconsistent relationship between hyperfiltration and glomer-
u/ar sclerosis in experimental renal disease. As I pointed out, a
compensatory increase in GFR follows renal ablation in the
human, dog, rabbit, and rat. This increase has been docu-
mented in single nephrons in dog and rat in micropuncture
studies. Because of the unique location of glomeruli on the
surface of the Munich-Wistar rat kidney, glomerular capillary
pressure has been measured directly only in this species. We
can reasonably assume that the factors that mediate the eleva-
tion of SNGFR in this species would lead to a rise in SNGFR in
all species. Why, then, does glomerular sclerosis only occur in
the rat?
One possibility is that the relationship between glomerular
hypertension and sclerosis is neither causal nor consistent.
Yoshida et al recently reported in abstract that, when glomer-
ular capillary pressure is measured repeatedly in the same
glomeruli of the rat remnant kidney over a 6-week period, so
that functional and structural changes can be monitored longi-
tudinally in each, the variations in SNGFR and capillary
pressures among glomeruli are not well correlated [38]. Whereas
the degree of glomerular sclerosis is greatest in the glomeruli
with the lowest GFRs, no correlation exists between the
ultimate level of SNGFR and the maximum glomerular capillary
pressure recorded in the earlier stage of the disease. These
studies suggest that glomerular hypertension is not necessarily
the forerunner of subsequent functional and structural damage.
Further, Purkerson and colleagues were able to reduce the
severity of progressive renal disease in rats with subtotal renal
ablation by using an inhibitor of thromboxane synthesis [391.
This protection occurred despite a near doubling of the GFR
and renal plasma flow rate, that is, despite marked hyperfiltra-
tion. Unfortunately, glomerular capillary pressure was not
measured in these experiments, and systemic blood pressure
was lower in the rats treated with the thromboxane inhibitor. It
is therefore possible that, if equivalent dilation of afferent and
efferent arterioles was achieved, a rise in plasma flow and GFR
could have occurred in the absence of a rise in glomerular
capillary pressure, especially if blood pressure was lowered.
Observations in experimental glomerular disease also argue
against the notion of a fixed relationship between hyperfiltration
and glomerular injury. In streptozotocin-induced diabetes mel-
litus, reversal of glomerular hypertension with a converting
enzyme inhibitor reduces proteinuria and the tendency of the
glomerulus to undergo sclerosis [34]. However, Bank and
colleagues, studying streptozotocin-induced diabetes in normo-
tensive (WKY) and hypertensive (SHR) rats, showed that
glomerular capillary pressure (Poc) is exaggerated in the SHR
rats within 7 days but that no differences in glomerular mor-
phology between normotensive and hypertensive animals were
evident after 6 months, despite the fact that the elevated POC
was sustained for this period [40]. In these studies, the normo-
tensive WKY diabetic rats had higher levels of PGC than did
their nondiabetic littermates and it could be argued that this
glomerular hypertension was sufficient to initiate the observed
mesangial expansion and proteinuria in this group. This, how-
ever, does not appear to be the case, because diabetic SHR rats
maintained normotensive with drugs had the same elevated PGC
as did diabetic WKY rats and yet had significantly less mesan-
gial expansion and proteinuria. These data thus fail to support a
causal relationship between glomerular capillary hypertension
and glomerular injury in this model. In the BB strain of rat with
congenital diabetes mellitus, GFR also increases early in life
above the levels observed in nondiabetic littermates, but with
no tendency toward the development of renal disease [22]. It is
not known whether glomerular hypertension occurs in this
model.
In doxorubicin- and puromycin-aminonucleoside-induced re-
nal injury in the rat, glomerular capillary pressure does not
appear to correlate with evolution of proteinuria or focal
glomerulosclerosis. Fogo and coworkers performed serial mi-
cropuncture measurements in the same glomeruli in both of
these disease models, and in preliminary studies found no
correlation between glomerular capillary pressure and glomer-
ular sclerosis [41]. Nevertheless, SNGFR declined progres-
sively due to focal glomerulosclerosis. Treatment with captopril
attenuated the degree of sclerosis without affecting SNGFR or
glomerular capillary pressure in the earlier stages. In short, the
development of glomerular sclerosis might not be related to the
occurrence of glomerular hypertension in a number of experi-
mental models of glomerular disease, even in the rat.
Lack of evidence that hyperfiltration leads to progressive
renal failure in humans. As I already mentioned, uninephrec-
tomy in renal transplant donors leads to hyperfiltration without
notable adverse effects in humans. In normal individuals, an
amino acid infusion [42] or a meat meal [35, 43] can induce
acute glomerular hyperfiltration. Chronic intravenous adminis-
tration of amino acids in patients receiving total parenteral
nutrition leads to nephromegaly [44]; renal size increases pro-
gressively as long as the parenteral nutrition is continued and
decreases when the infusion is discontinued. Abundant evi-
dence shows that renal size and GFR are positively correlated
in this setting [25] and we can assume that the GFR in such
individuals remains persistently elevated for the duration of the
parenteral nutrition. I am unaware of any reports of renal
damage during prolonged total parenteral nutrition. Taken
together, these considerations cast doubt on the causal relation-
ship between glomerular hypertension and progression of renal
disease in humans.
Secondary injury due to alterations in tubular and interstitial
function
The knowledge that calcium deposits commonly occur in the
interstitium of chronically diseased kidneys [45] led to a series
of rat studies that attempted to unravel the pathophysiologic
events leading to such deposition. The degree of calcification
and fibrosis appears to be closely correlated with serum phos-
phorus levels, and calcium-phosphate deposition occurred pre-
sumably as a consequence of a rise in the calcium-phosphorus
120 Nephrology Forum: Preventing the progression of human renal disease
product [46]. The logical preventive measure therefore was
restriction of dietary phosphorus intake. This maneuver proved
beneficial both in the rat remnant kidney [47] and in nephrotoxic
serum nephritis models [48]. Not only was proteinuria reduced
in both models, but so was mortality from renal failure.
Because renal calcification is a well-recognized complication
of the secondary hyperparathyroidism of uremia, the effect of
removal of the parathyroid glands was evaluated. Thyropara-
thyroidectomy proved effective in reducing the progression of
nephrotoxic serum nephritis, but selective parathyroidectomy,
surprisingly, was without effect [49]. The inevitable conclusion
that thyroid hormone is somehow linked to progression of renal
disease remained without further explanation for a number of
years. Recently, however, Conger and Falk reported prelimi-
nary data in the remnant kidney model which indicate that
thyroidectomy reduces SNGFR, glomerular capillary pressure,
and urinary protein excretion [50]. Replacement with thyroid
hormone or isoproterenol restored these parameters to prethy-
roidectomy levels. In view of the known tendency of hypothy-
roidism to attenuate the hvpertrophic response of the kidney,
and the ability of isoproterenol to reverse the effects of thyroid-
ectomy on GFR [50], thyroid hormone deficiency probably
reduces the likelihood that experimental renal disease will
progress. Unfortunately, these results do not elucidate the
mechanism of the protective effects of phosphate restriction.
Assessing the protective effect of phosphate restriction is
difficult because experimental phosphate restriction often is
accompanied by dietary protein restriction. Lumlertgul and
coworkers achieved isolated phosphate restriction in rats with
remnant kidneys by administering the phosphate binder dihy-
droxy-aluminum aminoacetate [51]. This approach produced no
change in protein intake or weight loss but nevertheless was
highly effective in reducing proteinuria and preventing the
long-term fall in GFR that occurs in these animals when they
are fed a phosphate-rich diet. Although the role of phosphate is
discussed here in the context of tubulointerstitial injury, it is
theoretically possible that the protective effects of phosphate
restriction are mediated by primary effects on glomerular func-
tion.
Nath et al have proposed an innovative explanation for the
progressive interstitial fibrosis that consistently appears in the
remnant kidney. Feeding rats bicarbonate reduced this fibrosis
[52]. The authors noted that bicarbonate-fed rats had fewer
deposits of C3 and C5b-9 than did sodium chloride-fed rats.
These authors proposed that the dietary alkaline load reduced
tubular ammonia production. Because nitrogen nucleophiles,
such as ammonia, react with complement component C3 to
form a convertase for the alternative complement pathway,
reduction of tissue levels of ammonia by bicarbonate was
thought to reduce tissue damage by this mechanism.
fficacy of therapy in human renal disease
Control of systemic blood pressure
Much emphasis has been placed on the observation that, in
any given patient, regardless of the nature of the disease
process, the reciprocal of the serum creatinine concentration
(1111Cr]) is a linear function of time and that a change in the slope
of this relationship reflects a change in the intrinsic rate of
progression [53]. The argument holds that if a linear decline in
l/[Crj is valid for all patients with all renal diseases, then
patients can serve as their own controls, and the need for
comparing different patient groups is obviated.
How infallible is this argument? Can the slope of the 1/[Cr]
relationship be altered by factors other than any single thera-
peutic modality under study? This issue has been raised by El
Nahas and Coles [54], who cogently point out that failure to
take into account spontaneous stabilization of renal function,
changes in muscle mass, alterations in creatinine intake, extent
of proteinuria and, importantly, the apparently beneficial effect
of frequent followup visits and blood pressure control might
account for some of the apparently beneficial results of protein
restriction and other manipulations. One example of the bene-
ficial impact of blood pressure control and close followup is
highlighted by two reports from the same laboratory. In 1983
Alvestrand and colleagues reported the beneficial effects of a
new amino acid preparation administered for an average period
of 224 days to 15 uremic patients [55]. In 4 patients in whom
progression of disease was assessed by the slope of 1/11Cr], renal
disease dramatically slowed or stopped. In these patients the
serum creatinine data were compared retrospectively with
prospective data gathered from the inception of the dietary
intervention. Three years later, the same group reported on 17
patients with chronic renal failure (creatinine clearance 12—66
mllmin) who were entered into a study that entailed no specific
dietary change but that required frequent followup and accept-
able blood pressure control [56]. (Of course, unintentional
changes in patients' dietary habits after enrollment that were
not directed by the study cannot be excluded.) The rate of
progression of renal failure slowed significantly after the pa-
tients entered the study. This important observation raises the
possibility that improvement in renal function that earlier had
been attributed to dietary manipulations might have had some
other cause.
It is accepted dogma that control of blood pressure limits
renal injury in essential hypertension and in experimental
models of hypertension. But careful documentation of the
effects of blood pressure control on progression of human renal
disease is limited. The role of blood pressure as a determinant
of the development of diabetic nephropathy recently has come
under scrutiny. Parving and coworkers found that diabetic
patients with proteinuria had higher blood pressures than did
diabetic patients without proteinuria when the groups were
matched for gender, age, body weight, and duration of diabetes
[571. Similar findings were reported from the Joslin Clinic,
where hypertension was found in 81% of juvenile-onset diabet-
ics with microalbuminuria but in only 32% of matched controls
without it [58]. A genetic predisposition to hypertension was
proposed as a major determinant of diabetic nephropathy [58].
Early, aggressive antihypertensive treatment for approximately
3 years has been shown to reduce the rate of decline of GFR in
the absence of a change in metabolic control of diabetes [59].
Baldwin and Neugarten summarized the evidence that control
of hypertension is beneficial in experimental models of glomer-
ular disease, in human glomerulonephritis, and in diabetic
nephropathy [601. Overwhelming evidence indicates that hyper-
tension aggravates glomerular injury in all circumstances and
that altered glomerular hemodynamics in disease magnifies the
transmission of the high systemic blood pressure to the glomer-
ulus, leading to an accelerated rate of injury [60]. Control of
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systemic hypertension thus plays a critical role in limiting
hemodynamic stress on the glomerulus [60].
Reduction of hemodynamically mediated glomerular injury
In the following section, I will analyze clinical studies de-
signed to retard the progression of renal disease, ostensibly by
reducing or reversing glomerular hypertension.
Dietary protein restriction. The effects of protein restriction
in azotemjc humans are difficult to evaluate in view of the
uncontrolled nature of most of the published studies. In 1975,
Johnson et al restricted protein intake and reduced phosphorus
absorption in patients with renal failure. The rise in serum
creatinine over the subsequent 2 years was slower than that
observed in untreated patients, but no controls were available
to determine the effect of close followup and blood pressure
control [61]. In 1982, Maschio and colleagues described the
effects of dietary protein and phosphorus restriction in 75
patients with renal failure followed for 18 to 76 months [621. The
slope of 1/[Cr] in patients with moderate (mean serum creati-
nine concentration, 2.18 mg/dl) and severe (mean serum creat-
mine, 4.2 mgldl) renal failure was reduced. These patients were
compared with a group of patients with a mean serum creatinine
of 2.28 mgldl who were ingesting an unrestricted diet. Fully 50%
to 80% of the patients were described as being hypertensive,
however, and no documentation is given as to the efficacy of
blood pressure control in the different groups. It is also not clear
whether the patients whose diets were restricted were moni-
tored more frequently than were untreated patients. A subse-
quent study by the same group examined the effects of a
low-protein diet in patients with chronic glomerulonephritis,
polycystic kidney disease, or chronic pyelonephritis [63]. The
untreated control group was studied retrospectively; thus it is
difficult to evaluate the claim that deterioration of renal function
was slowed.
El Nahas and coworkers also subdivided their patients ac-
cording to the nature of the underlying disease and were able to
demonstrate slowing of functional deterioration in the presence
of a low-protein diet only in the group with tubulointerstitial
disease [64]. This prospective study appears to have been well
controlled, with patients being followed for 6 months while
eating a normal-protein diet, and then for an additional 6
months eating a low-protein diet. No effect was seen in patients
with polycystic disease or hypertensive nephrosclerosis, and
only a marginal response was obtained in those with chronic
glomerulonephritis.
Low-protein diets have been supplemented with various
essential amino acids and keto-analogues of essential amino
acids in an attempt to maintain nitrogen balance [651. Despite
the ability of these diets to maintain positive nitrogen balance,
their value in arresting the progress of renal disease requires
further study. The studies by Alvestrand et al that I cited suffer
from the drawback that prospective and retrospective data are
compared [55]. Attman and colleagues found that residual renal
function continued to deteriorate over a mean followup period
of 5 months in a group of patients with diabetes and severe renal
failure (GFR in the range of 7.5 mL/min) who were treated with
a diet of 20 to 30 g/day of protein supplemented with essential
amino acids [65]. After 12 months, only 2 of 21 patients had not
developed progressive renal failure requiring dialysis or trans-
plantation.
Mitch et al treated 24 patients who had chronic renal failure
with a low-phosphorus diet containing 20 to 30 g of protein
supplemented with amino acids and their keto-analogues [661.
The decline in renal function slowed in 10 of 17 patients. Six of
these patients had a serum creatinine value of 8 mgldl or higher
at the time of entry; that value showed no tendency to decline
over an average of 22 months. Again, the effects of better blood
pressure control during the prospective phase of the study and
the proportion of patients with spontaneous stabilization of
function cannot be determined. Although the authors con-
tended that there is no evidence that progression of chronic
renal failure is slowed by more frequent visits," this conclusion
is open to question. A comparison of an average prospective
followup period of 20 months, with an average retrospective
evaluation period of 32 months, masks the fact that the fre-
quency of visits appears to have been much greater in the
prospective phase [66].
The only prospective, randomized trial reported thus far was
performed by Rosman et al, who followed 149 patients for at
least 18 months. The average rate of fall of lI[Cr] was signifi-
cantly slower in patients maintained on a diet of 0.4—0.6/kg body
weight of protein daily than in control patients who continued
their usual diet [67]. Control of blood pressure and serum
calcium and phosphorus was the same for all patients. Blood
pressure control was obtained with diuretics, beta blockers, and
vasodilators such as prazosin and hydralazine. The protective
effect of the low-protein diet was equally evident in patients
entering the study with GFRs less than 30 mllminll .73 m2 and in
patients with GFRs greater than 30 ml/min/l .73 m. Preliminary
data reported by Zeller and colleagues appear to confirm the
beneficial effects of dietary protein restriction in diabetic ne-
phropathy over 10 to 15 months in a randomized, prospective
study in which blood pressure was well controlled [681.
Pharmacologic manipulation of glomerular capillary pres-
sure. The observation that converting enzyme inhibitors im-
pede the progression of renal disease in rat models has raised
the possibility that such therapy might have a place in human
disease. Unfortunately little information is available in humans.
Taguma et al reported that captopril reduced proteinuria in
patients with advanced diabetic nephropathy [69], but the
duration of the study was too short to evaluate an effect on
GFR. A more recent report in insulin-dependent diabetics with
nephropathy showed that 12 weeks of captopril therapy re-
duced proteinuria but also caused a small but significant reduc-
tion in GFR [701. Although a reduction of GFR is not deleteri-
ous at this level of renal function and may, indeed, turn out to
be protective, it clearly indicates that converting enzyme inhib-
itors might have to be used with caution in diabetic patients
with advanced renal failure for fear of "tipping the scales" in a
previously stable patient, and thereby causing uremia.
Some investigators have inferred from the rat remnant kidney
model that converting enzyme inhibitors are more effective than
are other antihypertensive drugs in preventing progression of
renal disease [32—34]. In human disease, the validity of this
assertion needs to be established. As I discussed previously,
control of hypertension by conventional means does appear to
slow the progress of renal failure. But a theoretical problem that
could arise with the overly enthusiastic use of converting
enzyme inhibitors in advanced renal disease is that GFR could
fall in situations in which ultrafiltration strongly depends on
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efferent arteriolar tone. In moderate to severe renal failure in
hypertensive patients, this concern probably is not warranted,
because the current evidence suggests that GFR is well main-
tained [71]. It is not clear whether this finding applies to patients
with diabetic nephropathy.
If systemic hypertension is central to the progression of
human disease, antihypertensive agents are required that can
maintain renal plasma flow and GFR despite a reduction of
systemic blood pressure. Candidates for this role are the
dopamine agonists and the calcium channel-blocking agents.
Ibopamine, a dopamine-like agent, was effective in slowing
deterioration of, or even improving, renal function in patients
with nonglomerular renal diseases over a 6-month period [72].
Unfortunately, these studies also compared retrospective and
prospective data and, other than serum creatinine measure-
ments, no other renal functional parameters were provided.
Goldberg has suggested that, because a decrease in renal
perfusion is common in hypertensive states, and because hy-
pertension either causes, or is associated with, chronic renal
disease, activation of dopamine receptors might be useful in
preventing impairment of renal function. Dopamine itself is
unsuitable because of its poor bioavailability and alpha-adreno-
ceptor vasoconstrictor actions [73]. Potential candidates would
be oral agents that have effects mainly on dopamine 1 (DAI)
receptors, which predominate in the kidney. Such agents would
include levodopa and fenoldopam, which increase renal blood
flow while lowering blood pressure. The effects of calcium
channel blockers on renal hemodynamics are not well studied in
humans, but thus far these agents do not seem to depress GFR
in patients with compromised renal function [74].
Dietary phosphorus restriction. As I pointed out, it is diflicult
to separate the selective effects of protein restriction and
phosphorus restriction in low-protein diets; most early studies
combined restriction of both. Nevertheless, data in the litera-
ture do address the role of phosphorus intake in the rate of
progression of renal failure. Barsotti and coworkers reported on
2 comparable groups of patients with early chronic renal failure
[75]. Followed prospectively, these patients had the same
protein and caloric intake but different phosphorus intakes (6.6
versus 12.0 mg/kg/day). When the patients were switched from
their free diets to the controlled diets, creatinine clearances
were similar (20 mI/mm) and the rate of fall in creatinine
clearance slowed in both groups. Although a slower rate of
decline of renal function was observed in patients eating the
low-phosphorus diet, the final mean creatinine clearances dif-
fered only by 4 mI/mm at the end of 16 to 20 months. These
results are similar to those reported earlier by Barrientos et al,
who failed to find a protective effect of dietary phosphate
restriction on progression of renal disease [76].
Anticoagulant therapy, The role of microvascular coagula-
tion abnormalities in the progression of renal disease has been
suggested by anecdotal reports, but few controlled data are
available. The one controlled situation is in patients with
membranoproliferative glomerislonephritis. Donadio reported
that platelet inhibitor therapy with dipyridamole and aspirin
resulted in fewer cases of end-stage renal disease (3 of 21
patients after 62 months) when compared with a control group
(9 of 19 patients after 33 months) [77]. Zimmerman et al
conducted a similar prospective study using warfarin and dipy-
ridamole and showed stabilization of renal function in the
treated groups, but not in the control group [78]. When patients
were "crossed-over" (treatment to control and vice-versa),
significant changes in renal function were observed.
The concept of "glomerular tolerance"
Over the past few years, heavy emphasis has been placed on
the results of studies of animal models of renal disease. These
results point the way to new approaches for slowing the
progression of human renal disease. Important pathophysio-
logic principles have emanated from such studies, but important
pitfalls also have emerged. In many cases, the models are
sufficiently different from human disease—either quantitatively
or qualitatively—as to be of questionable relevance. Differ-
ences in the natural history of the same disease model from
species to species (such as the remnant kidney) highlight the
difficulty of simple extrapolation. Therapeutic maneuvers that
reduce glomerular hypertension are effective in slowing pro-
gression or reducing proteinuria in some animal models but not
in others. Finally, the evidence in support of the causal rela-
tionship between glomerular hypertension and progression of
renal disease in humans is tenuous.
In considering the results of these studies, I should like to
propose a hypothesis that could explain many, if not all, the
discrepant results, I have called this hypothesis "glomerular
tolerance." If, in a previously intact rat glomerulus, hemody-
naimc alterations are responsible for eventual proteinuria and
glomerular sclerosis, shouldn't these changes apply to all spe-
cies affected by a comparable degree of hyperfiltration? Perhaps
it is not the degree of hyperfiltration that causes injury, but also
the "tolerance" of the glomerulus to the hemodynamic stress.
That is, maybe quantitative differences in the threshold for
injury exist between intact and diseased nephrons in the same
species and between intact nephrons of different species.
This argument is supported by two sets of observations: (1)
The elevation in GFR following renal ablation is probably
similar in all species [25], as shown by micropuncture studies of
SNGFR in rats [30] and dogs [79] with remnant kidneys and by
the fact that, at minimum, a doubling of SNGFR must occur in
humans to restore serum creatinine concentration to normal
following unilateral nephrectomy [18]. (2) The rise in GFR that
follows a meat meal in humans, an increase that is termed
"renal reserve," is the same in normal kidneys as in diseased
kidneys [80]. Although initial studies suggested decreased "re-
nal reserve" in response to a meat meal in patients with renal
disease [43], recent studies show an intact "reserve" in such
patients [80, 81]. It is therefore unlikely that the magnitude of
the hyperfiltration is the variable that accounts for progression
of disease in one situation but not another.
The hypothetical concept of "glomerular tolerance" is illus-
trated in Figure 1, in which rats and humans are depicted as
having the same absolute level of SNGFR. The absolute rise in
GFR following renal ablation is similar in both. However, the
propensity for injury following renal ablation depends on the
relationship between the elevated GFR and some hypothetical
injury threshold. The analogy could be equally applied to the
streptozotocin-induced versus the BB diabetic rat; the injury
threshold may simply be higher in the latter. This hypothesis
proposes that it is not "renal reserve" that predicts the ten-
dency toward progression of disease, but some other parame-
ter(s) reflecting susceptibility to injury. One explanation for
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Fig. 1. The concept of glomerular tolerance as illustrated by a compar-
ison of the response of the glo,nerulus in the human and the rat to renal
ablation. The basal GFR and the increase in GFR following renal
ablation are similar (dark arrows). The hypothetical difference between
the two species is that the injury threshold (open arrows) is greater in
humans than in rats. Thus, the hemodynamic adaptation approaches the
injury threshold more readily in rats than in humans, making the
glomerulus of the former more susceptible to injury.
such a variable susceptibility could be differences in the auto-
regulatory capacity of the glomerulus, such that systemic blood
pressure is transmitted more effectively to the glomerular
capillaries in certain species or disease states than in others [82,
83]. This variation might be due to differences in the production
of, or sensitivity to, vasoactive substances within the kidney or
to intrinsic structural constraints.
Concerning clinical trials designed to retard the progression
of renal disease, a study that separates the effects of selective
reduction of glomerular hypertension and the effects of reduc-
tion of systemic hypertension in humans has not been carried
out. To date, it appears that control of blood pressure is of
central importance in this regard. There also appears to be a
protective effect of low-protein diets, but the paucity of ade-
quately controlled, prospective studies in patients leaves the
value of this approach unproved. Furthermore, it is not clear
whether dietary changes affect different disease states differ-
ently for any given level of renal function. Finally, there is no
convincing evidence that selective reduction of phosphorus
intake or absorption alters the course of human renal disease
despite the evidence for such an effect in animals.
Let us return to my hypothetical concept of "glomerular
tolerance." If glomerular tolerance could be measured in hu-
mans, it might be used as a predictor of progression of renal
disease. I wish to propose a method for making such measure-
ments. Two tests might be assessed: the response of proteinuria
to colloid-induced volume expansion and the response to di-
uretic-induced volume contraction. One possible method would
be to measure glomerular permselectivity to macromolecules
(that is, proteinuria) in response to acute hyperfiltration. The
fact that normal rats develop proteinuria in response to an acute
protein load [84] and humans do not [80] suggests that changes
in proteinuria might be a useful reflection of glomerular toler-
ance to hyperfiltration. For example, if uninephrectomy or
intrinsic disease leads to subtle glomerular injury that does not
cause overt signs of disease in the remaining nephrons, it might
be possible to expose the silent initial damage by the superim-
posed stress of acute hyperfiltration. This maneuver, if it
induced proteinuria, might thereby identify patients with low-
ered injury thresholds, that is, those more susceptible to the
effects of long-term glomerular hypertension. Because urinary
protein excretion does not seem to increase after an acute oral
protein load in humans, even when biopsy-proved glomerular
disease is present [80], a more reasonable approach might be to
evaluate the effects of acute colloid volume expansion, which
increases both albumin and IgG excretion in nephrotic patients
but not in normal subjects [85]. This maneuver perhaps could
identify a subgroup of patients with reduced glomerular toler-
ance.
A critical question remains: Are there, indeed, subpopula-
tions of patients with decreased glomerular tolerance who show
no manifestations of overt disease under baseline conditions,
but who manifest proteinuria following an acute stress such as
uninephrectomy? If such subpopulations could be defined, we
could reasonably predict which patients are more likely to
develop overt disease at a later stage, and we could thus
institute preventive therapy selectively and appropriately. Fur-
thermore, if maneuvers such as acute diuretic-induced volume
contraction or low-protein intake [86] lead to decreased protein
excretion in a subpopulation of patients with established gb-
merular disease, it would be reasonable to predict that these
patients would benefit from a reduction of hemodynamic stress.
The use of hyperoncotic albumin infusion as a proteinuric
stimulus or the use of acute volume contraction to reduce
proteinuria in patients with established glomerulopathies might
prove useful methods of selecting patients who would benefit
from a reduction in hemodynamic stress to the glomerulus. If an
adaptation in glomerular function is beneficial and does not
approach the injury threshold, the adaptation should be sup-
ported. On the other hand, if the adaptation exceeds this
threshold, it should be prevented or reversed so as to preserve
function. Currently there is no method for detecting and quan-
titating such a hypothetical threshold for injury.
An encouraging start has been made in understanding the
factors that cause progression of human renal diseases. The
time has come for us to apply more quantitative approaches to
human studies, not only for assessing outcome but for predict-
ing the response to therapy. This will enable physicians to
select patients for different forms of treatment and thus to
optimize the results of therapy.
Questions and answers
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center, Boston,
Massachusetts): Perhaps you can clarify your concept of "gb-
merular tolerance." You propose to use hyperoncotic albumin
and diuretics to assess this function. I assume you are propos-
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ing that such tests be assessed, not that they be used clinically.
Is that correct?
DR. FINE: Absolutely correct. I did not want to come here
simply having analyzed the data in order to draw limited
conclusions. I thought that if one could look at the data in
experimental animals and then ask some questions pertinent to
human disease, it might be possible to put the whole therapeutic
approach into some sort of unifying conceptual framework.
This is why I'm suggesting the term "glomerular tolerance."
One looks at the relationship between the stress and the
tolerance of the nephrons to that stress rather than just looking
at the stress, as everybody has done up to now. But you are
entirely correct; the last part of what I talked about is simply a
series of suggestions about how we might start thinking about
this.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center): Dr. Fine, you pointed out that
various species exhibit hyperfiltration following partial renal
ablation, but that only the rat develops glomeruloscierosis.
What do you think is the basis for that? Do you imply that for
the same change in GFR, the glomerular capillary pressure is
different among the various species? Is it possible that the
difference reflects, at least in part, variable degrees of renal
ablation and differences in the time frame over which observa-
tions are made? Finally, referring to your concept of "glomer-
ular tolerance," what is the evidence that the hemodynamic
stress to the glomerulus is similar across species?
DR. FINE: That is a key question and an unanswerable one
because, even in the rat, glomerular capillary pressure can be
measured directly only in the Munich-Wistar strain. In other
strains, glomerular capillary pressure can be measured indi-
rectly from stopped flow pressure. Unfortunately no pertinent
data exist in rabbit or dog models. All I can tell you is that
hyperfiltration does occur in all species. It occurs in humans
and in the rabbit, as evidenced by total GFR measurements; in
the rat and the dog it has been documented at the single nephron
level. I suppose that it is theoretically possible that in the rabbit,
in the dog, and in humans hyperfiltration occurs by virtue of a
rise in plasma flow without glomerular hypertension and that
this could be an alternative explanation as to why these species
do not develop glomerulosclerosis. I would be surprised if this
is the case. In fact, Brian Myers' group, who measured changes
in derived glomerular capillary pressure (but not absolute
values) in humans, showed that an acute meat meal elevates
Poc when GFR rises [80]. Thus, given the fact that the problem
only occurs in one of four species, it is very difficult to apply
principles derived from that species across species barriers
because they simply might not be applicable. The one explana-
tion I have focused on is an alteration in the injury threshold.
You have stressed something that, perhaps, I should have
emphasized, that is, that the magnitude of the stress can differ
from species to species.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): In your analysis
you seemed particularly impressed by the efficacy of blood
pressure control in ameliorating the progression of chronic
renal disease. Do you think that the mechanism involved is
simply a reduction in glomerular hydraulic pressure, or does
one have to invoke an additional mechanism?
DR. FINE: Basically, the mechanism is probably a reduction
of transmitted pressure, but I refer you to a very good review on
this topic by Baldwin and Neugarten [60]. It does appear as if
higher systemic blood pressures are transmitted to the glomer-
ulus. Thus, in humans at least, whatever method you use for
reducing pressure does seem to have a protective effect.
DR. KASSIRER: Do we know anything more about the mech-
anisms by which changes in protein or amino acid intake change
the GFR?
DR. FINE: The current investigative enthusiasm suggests that
many people have tried to answer that question by identifying
one or more humoral factors released in response to the protein
or amino acid. Changes in GFR could, of course, be a direct
effect on the glomerulus of raising the concentration of one or
more amino acids. This seems less likely than the possibility
that the dietary manipulation alters the level of one or more
systemic or local hormones. The candidate hormones include
growth hormone, glucagon, atrial natriuretic factor, and some
of the vasodilator prostaglandins. Thus far no one has identified
a single hormone, and because of what we know about what
controls glomerular circulation, the mechanism is unlikely to be
a single substance.
DR. PAUL S. KURTIN (Chief, Division of Pediatric Nephrol-
ogy, New England Medical Center): What role, if any, do you
think continuing growth of the organism plays? For example,
the rats used in most studies are young rats that are growing
throughout the study, whereas adult kidney donors are no
longer growing. The difference might be important in light of a
report of 8 children with unilateral renal agenesis who devel-
oped focal and segmental glomerulosclerosis in the remaining
kidney [871.
Da. FINE: Dogma says that older patients do not undergo, or
do not demonstrate, renal hypertrophy to the same extent as do
younger patients. You are also suggesting that because hyper-
trophy seems to be closely linked to GFR and because humans
don't show the sclerotic response, maybe the GFRs are not
elevated. I have shown representative data indicating that
human donors do, in fact, have elevated GFRs even though
they are an older, mature population [18]. Their kidneys still
undergo hypertrophy and hyperfiltration, so I don't think that
the answer lies in the age at all. In fact, most renal donors are
in the age group in whom satisfactory and complete hypertro-
phy and hyperfiltration do occur.
DR. KURTIN: But would you comment on McCluskey's data?
DR. FINE: The question with those data, whether they pertain
to unilateral renal agenesis or reflux nephropathy, is: how do
you confidently separate primary injury from secondary injury?
The primary disease is a compounding factor and can affect the
remaining kidney the same way it induced the initial injury. It
may be true that the hemodynamic stress accentuates disease,
but I think that it's very difficult to sort out when you've got
some primary, underlying renal injury to contend with.
DR. RONALD D. PERRONE (Division of Nephrology, New
England Medical Center): I think one of the problems with the
Rosman study, which purported to show the benefit of protein
restriction, is that the patients with low creatinine clearance
who were assigned to a low-protein diet had a reduction in
creatinine excretion towards the end of the study [67]. Rosman
et al did not measure arm circumference, so it is unclear
whether there was loss of muscle mass.
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DR. FINE: In fact, the study you cite measured survival
curves. You probably cannot do better than that.
DR. PERRONE: I would take it one step further. Although
Mitch and coworkers have advocated the use of the reciprocal
of serum creatinine [66], they previously reported that extrare-
nal creatinine metabolism takes on a significant role in patients
with advanced renal failure [88]. It is possible that extrarenal
creatinine degradation is an additional mechanism for stabiliza-
tion of the serum creatinine in those patients.
DR. FINE: Yes, it is possible. One is forced to conclude that
such studies should be conducted not only prospectively but
with a more rigorous marker of GFR than the serum creatinine
concentration.
DR. MADIAS: You referred to a difference between the BB
diabetic rat and the rat with streptozotocin-induced diabetes in
terms of development of advanced renal dysfunction, and you
implied that renal disease might be an idiotypic feature of
treatment with streptozotocin. What about other models of
diabetes mellitus, for example, those induced by alloxan or
pancreatectomy? Do they get renal damage?
DR. FINE: Since renal hypertrophy does occur in alloxan-
induced diabetes [89], I assume that GFR also rises. I have no
idea whether renal damage has been described in this model.
Certainly streptozotocin is the most widely used experimental
agent.
DR. KASSIRER: Let me offer a thought about the protein-
restriction studies. Perhaps protein restriction is not highly
efficacious, but because patients are now being followed much
more closely and carefully, and blood pressure is being brought
under control better (particularly with the effective drugs now
available), renal function is better preserved now than it was
before.
DR. FINE: I think that is partially true. We probably will find
that in all ongoing studies the control groups will do consider-
ably better than anybody has anticipated because of the close
control of blood pressure. I think that your pessimism (and I
hope that's too strong a word) about the effect of the protein
diet might not be correct; there might be, and probably will be,
an additional effect of a low-protein diet when all the data come
in. But you're right about the control groups. In talking to
colleagues, it is evident to me that this is now the general
experience in treating patients with renal disease. Our patients
seem to be doing much better than we would have anticipated at
first visit, when they arrive with a serum creatinine concentra-
tion of 5 or 6 mgldl. The patient presented today represents an
example of this. Thus close followup needs to be stressed.
DR. HARRINGTON: Dr. Fine, you mentioned in passing the
data of Alfrey regarding the rat subjected to thyroparathy-
roidectomy. The effects demonstrated were related to the
presence or absence of the thyroid gland, not the parathyroid
gland. Perhaps you could expand on that fascinating observa-
tion. Should we make all our patients hypothyroid!?
DR. FINE: Certainly not! Other than the observation that if a
uninephrectomy is performed in a hypothyroid animal there is
less tendency for the remaining kidney to hypertrophy [901, the
simple explanation is that there is less tendency for the GFR to
increase in hypothyroidism. Preliminary data suggest that the
GFR decreases in a hypothyroid animal [50]. Thus the protec-
tive effect of thyroparathyroidectomy also might be mediated
through a hemodynamic mechanism. If the hypothroid animal is
given isoproterenol to restore the cardiac output and restore
GFR, the selective effects of thyroid hormone deficiency can be
studied independently of the hemodynamic effects. The results
of such studies would be interesting, but my guess is that a
hemodynamic event is playing a role in the protection afforded
by thyroidectomy. I also remind you that these preliminary
studies were performed in rats.
DR. PERRONE: I am intrigued by the protective effect of
hypothyroidism. As we know, thyroid hormone stimulates
sodium-potassium ATPase. Have there been any studies on the
metabolic effects of low-protein diets or other protective ma-
neuvers? Might not hemodynamic effects on metabolism, for
example, be part of the protective effect?
DR. FINE: That is possible. I don't know of any studies that
address your question directly. I think it is appropriate that
these suggestions be raised; we clearly need to think about this
problem as broadly as possible.
DR. HARRINGTON: Is there any evidence that the degree of
reduction of blood pressure has a progressively protective
effect? If you lower blood pressure to the upper level of normal,
to normal, or to slightly below normal, do you obtain a
differential effect on preservation of renal function?
Da. FINE: I don't know of any data measuring that. Clearly it
would be a very difficult study. As we all know, when we ask
our patients to measure their blood pressures at home and to
write down the results, we are presented with numbers that
often bear very little relationship to those we obtain from blood
pressure measurements in the office. Perhaps the 24-hour
monitoring approach will provide us with better data to evaluate
this possibility.
DR. MADIAS: Christensen and Mogensen reported on a small
group of patients with incipient diabetic nephropathy (that is, at
the microalbumipuric stage) and mild hypertension (baseline of
135/93 mm Hg) who were treated with cardioselective beta
blockers and diuretics [91]. Followup for a mean of 3 years
revealed that reduction of blood pressure to an average of
125/84 mm Hg was associated with reversal of the pattern of
urinary albumin excretion from a mean yearly increase of 18%
prior to treatment (as judged by, on average, 5 years of
observation) to a mean yearly decrease of 21% following
commencement of antihypertensive therapy. Glomerular filtra-
tion rate was supernormal at baseline and remained stable
throughout the observation period.
DR. VINCENT CANZANELLO (Division of Nephrology, New
England Medical Center): In your scheme for determining who
will respond to further dietary manipulation, could the use of a
converting enzyme inhibitor (CE!) potentially replace diuretic-
induced volume depletion?
DR. FINE: It could, only if a CE! has the desired effect on the
final measurement, which is a change in protein excretion.
There is now evidence that converting enzyme inhibition does
reduce proteinuria [92]. You could argue that if a CEI reduces
the proteinuria acutely, that this would be appropriate long-
term therapy. The problem is that it's entirely possible that any
other method of reducing systemic blood pressure might be
equally protective. I suppose that what I'm ultimately asking
for is for a general approach that looks at the question of
whether it is possible, by a small battery of tests, to predict
whether a specific therapy will be successful. For the patient,
generally a low-protein diet is a major compromise in lifestyle.
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Let's try to be scientific and predictive about who should be
treated with a given modality. I'm simply raising this question:
Can we start looking for these things in humans, rather than
rats, so as to decide whether a given patient is going to respond?
DR. MADIAS: In view of the experiment you cited in which
administration of sodium bicarbonate apparently reduced the
magnitude of the interstitial disease in rats with the remnant
kidneys 1521, could we imply that—or at least question whether—
one of the ways that high-protein diets exert their injurious
effects might be through increasing the endogenous acid load?
DR. FINE: That's a good suggestion and, as far as I know, one
that has not been addressed. I would caution you, however. For
some peculiar reason, in certain rodent species the interstitial
disease tends to be more prominent than in others. For in-
stance, this presumably contributes to progressive renal disease
in the rabbit with a remnant kidney [4, 8]. Most human renal
diseases show both glomerular and interstitial components, but
one never knows how much the primary interstitial injury
contributes to the decline in function, It is clearly an adaptation
that needs to be investigated.
Da. MADIAS: You mentioned that following partial nephrec-
torny, the glomeruli enlarge. Is there a structural component to
this enlargement, or does it merely reflect vascular engorge-
ment secondary to increased blood flow?
DR. FINE: At one time, micropuncture measurements led to
the belief that surface area did not increase; today the consen-
sus is that the glomeruli are larger than the controls when
studied in vitro. This finding indicates an intrinsic structural
enlargement because it occurs in non-perfused glomeruli.
DR. MADIAS: Were various studies that examined the effect
of protein restriction on the progression of renal diseasç con-
trolled for the amount of energy and other nutrients the diet
supplied?
DR. FINE: Generally not. Recent animal studies have raised
the possibility that carbohydrate restriction preserves the renal
parenchyma in rats 1931, and no doubt human studies will
follow.
DR. DEMETRIOS VLAHAKOS (Division of Nephrology, New
England Medical Center): You showed us evidence suggesting
that hypothyroidism, associated with a decreased metabolic
rate, might protect the kidney. Is it possible that the uniqueness
of the rat is based on its fast metabolic rate and that, if we wait
longer for dogs and humans, we will find the same changes in
the kidneys as we found in a shorter period of time in rats?
DR. FINE: I can't answer that question. I didn't address the
issue of hypothyroidism other than to show that the protection
achieved by dietary phosphate restriction was not mediated by
parathyroid hormone. One is left with the conclusion that there
might be a role for the thyroid, but there is no reason to suggest
that an intrinsic alteration in thyroid function is a primary cause
of the problem.
DR. MARY FOSTER (Division of Nephrology, New England
Medical Center); I am interested in the difference in the rats and
other species. In a recent report, Schwartz and colleagues
examined epithelial cell function in a remnant kidney model in
Sprague-Dawley rats [94]. Examination of the kidneys 6 weeks
postoperatively revealed changes in arterioles and glomeruli
that resembled changes associated with malignant hyperten-
sion. The authors proposed that in this strain of rat, the remnant
kidney model is most similar to human malignant nephroscle-
rosis. They did see some segmental sclerosis at 6 weeks. Has
this been seen in other models?
DR. FINE: No, because the other models do not develop the
renal lesion. M far as I know, the canine remnant kidney has
not been looked at carefully in this regard, and there is no
evidence in humans that if you give away one kidney you
automatically start developing vascular lesions in the other.
DR. FOSTER: One of their control groups was the spontane-
ously hypertensive rat (without nephrectomy) that had elevated
systemic blood pressures similar to the blood pressures of the
nephrectomized Sprague-Dawley rats [93]. The spontaneously
hypertensive model did not demonstrate the renal vascular
changes.
DR. FINE: You are saying that at the same level of hyperten-
sion, vascular changes were seen in the remnant kidney but not
in the intact kidney of spontaneously hypertensive rats. This
adds further complexity to our understanding of the unique
features of the rat remnant kidney and .poipts to decreased
glomerular tolerance, perhaps associated with abnormal auto-
regulation.
Reprint requests to Dr. L. Fine, Division of Nephrology, Department
of Medicine, UCLA Schpol of Medicine, Los Angeles, Caltfornia,
90024-1689, USA
References
1. CHANUTIN A, FERRIS EB: Experimental renal insufficiency pro-
duced by partial nephrectomy. I. Control diet. Arch Intern Med
49:767—787, 1932
2. SHIMAMURA T, MORRISON AU: A progressive glomerulosclerosis
occurring in partial five-sixths nephrectomized rats. Am J Pathol
79:95—lOg, 1975
3. PURKERSON ML, HOFFSTEN PE, KLAHR S: Pathogenesis of the
glomerulopathy associated with renal infarction in rats, Kidney mt
9:407—417, 1976
4. FINE LG, TRIZNA W, BOURGOIGNIE JJ, BRICKER NS: Functional
profile of the uremic nephron. Role of compensatory hypertrophy
in the control of fluid reabsorption by the proximal straight tubule.
J C/in Invest 61:1508—1518, 1978
5. FINE LG, SCHLONDORFF D, TRIZNA W, GILBERT RM, BRICKER
NS: Functional profile of the isOlated uremic nephron. Impaired
water permeability and adenylate cyclase responsiveness of the
cortical collecting tubule to vasopressin. JClin Invest 61:1519—
1527, 1978
6. FINE LG, YANAGAWA N, SCHULTZE RG, TUCK M, TRIZNA W:
Functional profile of the isolated uremic nephron. Potassium adap-
tation in the rabbit cortical collecting tubule. J Clin Invest 64:
1033—1043, 1979
7. TRIZNA W, YANAGAWA N, BAR-KHAYIM Y, HOUSTON B, FINE
LG: Functional profile of the isolated uremic nephron. Evidence of
proximal tubular "memory" in experimental renal disease. J C/in
Invest 68:760—767, 1981
8. EDDY AA, FALK RJ, SIBLEY RK, HOSTETFER TM: Subtotal ne-
phrectomy in the rabbit: a modelof chronic hypercaleemia, nephro-
lithiasis, and obstructive nephropathy. J Lab C/in Med 107:508—
516, 1986
9. WEN SF, WONG NLM, EvANSON RL, LOCKHART EA, DIRKS JH
Micropuncture studies of sodium transport in the remnant kidney of
the dog: The effect of graded volume expansion. I Clin Invest
52:386—397, 1973
10. ROBERTSON JL, GOLDSCHMIDTM, KRONFELD DS, TOMASZEWSKI
JE, HILL GS, BOVEE KC: Long-term renal responses to 'high
dietary protein in dogs with 75% nephrectomy. Kidney Int 29:511—
519, 1986
11. REISELBACH RE, SHANKEL SW, SLATOPOLSKY E, LuBowITz H,
BRICKER NS: Glucose titration studies in patients with chronic
progressive renal disease. J C/in Invest 46:157—163, 1967
Nephrology Forum: Preventing the progression of human renal disease 127
12. SLATOI'OLSKY E, ELKAN 10, WEERTS C, BRICKER NS: Studies on
the characteristics of the control system governing sodium excre-
tion in uremic man. J C/in Invest 47:521—530, 1968
13. SLATOPOLSKY E, HOFFSTEN P, PURKERSON M, BRICKER NS: On
the influence of extracellular fluid volume expansion and of uremia
on bicarbonate reabsorption in man. J C/in Invest 49:988—998, 1970
14. OLSON JL, HOSTETTER TH, RENNKE HG, BRENNER BM,
VENKATACHALAM MA: Altered glomerular permselectivity and
progressive sclerosis following extreme ablation of renal mass.
Kidney mt 22:112—126, 1982
15. HOSTETTER TH, MEYER TW, RENNKE HG, BRENNER BM: Chronic
effects of dietary protein on renal structure and function in the rat
with intact and reduced renal mass. Kidney mt 30:509—517, 1986
16. RUTHERFORD WE, BORDIER P, MARIE P, HRUSKA K, HARTER H,
BLONDIN AJ, HADDAD J, BRICKER N, SLATOPOLSKY E: Phosphate
control and 25-hydroxycholecalciferol administration in preventing
experimental renal osteodystrophy in the dog. J C/in Invest 60:
332—341, 1977
17. HAKIM RM, GOLDSZER RC, BRENNER BM: Hypertension and
proteinuria: Long-term sequelae of uninephrectomy in humans.
Kidney lnt 25:930—936, 1984
18. MILLER IL, SUTHANTHIRAN MS, RIGGI0 RR, WILLIAMS JJ,
RIEHLE RA, VAUGHAN DE, STUBENBORD WT, MOURADIAN J,
CHEIGH iS, STENZEL KH: Impact of renal donation: Long-term
clinical and biochemical follow-up of living donors in a single
center. Am J Med 79:201—208, 1986
19. ROBITAILLE P, MONGEAU J, LORTIE L, SINNASSAMY P: Long-term
follow-up of patients who underwent unilateral nephrectomy in
childhood. Lancet 2:1297—1299, 1985
20. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake
and the progressive nature of kidney disease: The role of hemody-
namicalty mediated glomerular injury in the pathogenesis of pro-
gressive glomerular sclerosis in aging, renal ablation, and intrinsic
renal disease. N Engi J Med 307:652—659, 1982
21. HOSTETTER TH, TROY JL, BRENNER BM: Glomerular hemodynam-
ics in experimental diabetes mellitus. Kidney Int 19:410—415, 1981
22. BROWN DM, STEFFES MW, THIBERTP, AZAR 5, MAUER SM:
Glomerular manifestations of diabetes in the BB rat. Metabolism
32:131—135, 1983
23. OLIvER J: Architecture of the Kidney in Chronic Bright's Disease.
New York, Hoeber, 1939
24. ICHIKAWA I, HOYER JR, SElLER MW, BRENNER BM: Mechanism
of glomerulotubular balance in the setting of heterogeneous glomer-
ular injury. Preservation of a close functional linkage between
individual nephrons and surrounding microvasculature. J C/in
Invest 69:185—198, 1982
25. FINE LG: The biology of renal hypertrophy. Kidney Int 29:619—634,
1986
26. DITZEL J, SCHWARTZ M: Abnormally increased glomerular filtra-
tion rate in short-term insulin-treated diabetic subjects. Diabetes
16:264—267, 1967
27. MOGENSEN CE: Renal function changes in diabetes. Diabetes
25:872—879, 1976
28. CHRISTIANSEN JS, FRANDSEN M, PARVING H-H: The effect of
intravenous insulin infusion on kidney function in insulin-depen-
dent diabetes mellitus. Diabetologia 20:199-204, 1981
29. BRENNER BM: Nephron adaptation to renal injury or ablation. Am
J Physiol 249 (Renal Fluid Electrolyte Physiol l8):F324—F337, 1985
30. HOSTETTER TH, OLSON JL, RENNKE HG, VENKATACHALAM MA,
BRENNER BM: Hyperfiltration in remnant nephrons: a potentially
adverse response to renal ablation. Am J Physiol 241 (Renal Fluid
Electrolyte Physiol l0):F85—F93, 1981
31. NATH KA, KREN SM, HOSTETTER TH: Dietary protein restriction
in established renal injury in the rat: Selective role of glomerular
capillary pressure in progressive glomerular dysfunction. J C/in
Invest 78:1199—1205, 1986
32. ANDERSON 5, MEYER TW, RENNKE HG, BRENNER BM: Control of
glomerular hypertension limits glomerular injury in rats wth re-
duced renal mass. J C/in Invest 76:612—619, 1985
33. ANDERSON S. RENNKE HG, BRENNER BM: Therapeutic advantage
of converting enzyme inhibitors in arresting progressive renal
disease associated with systemic hypertension in the rat. J C/in
Invest 77:1993—2000, 1986
34. ZATZ R, DUNN BR, MEYER TW, ANDERSON 5, RENNKE GH,
BRENNER BM: Prevention of diabetic glomerulopathy by pharma-
cological amelioration of glomerular capillary hypertension. J Clin
Invest 77: 1925—1930, 1986
35. HOSTETTER TH: Human renal response to a meat meal. Am J
Physio/ 250 (Renal Fluid Electrolyte Physiol l9):F6l3—F6l8, 1986
36. HARRIS DCH, HAMMOND WS, BURKE TJ, SCHRIER RW: Verapa-
mil protects against progression of experimental chronic renal
failure. Kidney mt 31:41—46, 1987
37. Gotioosce MS, CHAIMOVITZ C, RAPOPORT J, GOLDSTEIN J, KOL
R: Calcium metabolism in uremic nephrocalcinosis: Preventive
effect of verapamil. Kidney mt 27:774—779, 1985
38. YOSHIDA Y, Focio A, KIKUCHI T, GLICK A, ICHIKAWA 1: Serial
micropuncture analyses of the same nephrons in chronic renal
diseases: A test for the hyperfiltration theory (abstract). Kidney mt
31:394, 1987
39. PURKERSON ML, JOIST JH, YATES J, VALDES A, MORRISON A,
KLAHR S: Inhibition of thromboxane synthesis ameliorates the
progressive kidney disease of rats with subtotal renal ablation. Proc
Nat! Acad Sci USA 82:193—197, 1985
40. BANK N, KLOSE R, AYNEDJIAN HS, NGUYEN D, SABLAY LB:
Evidence against increased glomerular pressure initiating diabetic
nephropathy. Kidney mt 31:898—905, 1987
41. FoGo A, YOSHIDA Y, KIKUCHI T, GLICK A, ICI-IIKAWA I: Serial
micropuncture analysis of the same nephrons in chronic renal
diseases (CRD): Studies in two rat models of glomerular sclerosis
(GS) (abstract). Kidney mt 3 1:384, 1987
42. CASTELLINO P, CODA B, DEFRONZO RA: Effect of amino acid
infusion on renal hemodynamics in humans. Am J Physiol 251
(Renal Fluid Electrolyte Physiol 20):F132—Fl40, 1986
43. BoscH JP, SACCAGGI A, LAUER A, RoNco C, BELLEDONNE M,
GLABMAN 5: Renal functional reserve in humans: Effect of protein
intake on glomerular filtration rate. Am J Med 75:943—950, 1983
44. COCHRAN ST, PAGANI JJ, BARBARIC ZL: Nephromegaly in hyper-
alimentation. Radiology 130:603—606, 1979
45. IBELS LS, ALEREY AC, HUFFER WE, CRASWELL PW, WElL R:
Calcification in end-stage kidneys. Am J Med 7 1:33—39, 1981
46. HAUT LL, ALFREY AC, GUGGENHEIM S. BUDDINGTON B,
SCHRIER N: Renal toxicity of phosphate in rats. Kidney Int 17:
722—731, 1980
47. IBELS LS, ALFREY AC, HAUT LL, HUFFER WE: Preservation of
function in experimental renal disease by dietary restriction of
phosphate. N EngI J Med 298:122—126, 1978
48. KARLINSKY ML, KAUT LL, BUDDINGTON B, SCHRIER NA,
ALFREY AC: Preservation of renal function in experimental glomer-
ulonephritis. Kidney Int 17:293—302, 1980
49. TOMFORD RC, KARLINSKY ML, BUDDINGTON B, ALFREY AC:
Effect of thyroparathyroidectomy and parathyroidectomy on renal
function and the nephrotic syndrome in rat nephrotoxic serum
nephritis. J C/in Invest 68:655—664, 1981
50. CONGER JD, FALK SA: The protective mechanism of thyroidec-
tomy in chronic renal failure (abstract). Kidney Int 3 1:381, 1987
51. LUMLERTGUL D, BURKE TJ, GILLUM DM, ALFREY AC, HARRIS
DC, HAMMOND WS, SCHRIER RW: Phosphate depletion arrests
progression of chronic renal failure independent of protein intake.
Kidney lnt 29:658—666, 1986
52. NATH KA, HOSTETTER MK, HOSTETTER TH: Pathophysiology of
chronic tubulo-interstitial disease in rats: Interactions of dietary
acid load, ammonia, and complement component C3. J C/in Invest
76:667—675, 1985
53. MITCH WE: The influence of the diet on the progression of renal
insufficiency. Annu Rev Med 35:249—264, 1984
54. EL NAHAS AM, COLES GA: Dietary treatment of chronic renal
failure: Ten unanswered questions. Lancet 1:597—600, 1986
55. ALVESTRAND A, AHLBERG M, FURST P, BERGSTROM J: Clinical
results of long-term treatment with a low protein diet and a new
amino acid preparation in patients with chronic uremia. C/in
Nephro/ 19:67—73, 1983
56. BERGSTROM J, ALVESTRAND A, BUCHT H, GUTIERREZ A: Progres-
sion of chronic renal failure in man is retarded with more frequent
clinical follow-ups and better blood pressure control. C/in Nephrol
25:1—6, 1986
57. PARVING HH, ANDERSEN AR, SMIDT UM, OXENBOLL, EDSBERG
128 Nephrology Forum: Preventing the progression of human renal disease
B, CHRISTIANSEN JS: Diabetic nephropathy and arterial hyperten-
sion. Diabetologia 24:10—12, 1983
58. KItOLEWSKI AS, WARRAM JH, CHRISTLIEB AR, BUSICK EJ, KAHN
CR: The changing natural history of nephropathy in type! diabetes.
Am J Med 78:785—794, 1985
59. PARVING HH, SMIDT UM, ANDERSEN AR, SVENDSEN PA: Early
aggressive antihypertensive treatment reduces rate of decline in
kidney function in diabetic nephropathy. Lancet 1:1175—1178, 1983
60. BALDWIN DS, NEUGARTEN J: Blood pressure control and progres-
sion of renal insufficiency, in The Progressive Nature of Renal
Disease, edited by MITCH WE, BRENNEI& BM, STEIN JH, New
York, Churchill Livingstone, 1986, pp 81—110
61. JOHNSON WJ, GOLDSMITH RS, JOWSEY J, FT AL: The influence of
maintaining normal serum phosphate and calcium on renal osteo-
dystrophy, in Vitamin D and Problems Related to Uremic Bone
Disease, edited by NORMAN AW, SCHAEFER K, GRIGIOLEIT HG,
VON HERRATH D, RITZ E, New York, Walter de Gruyter, 1975, p
513
62. MA5cHIO G, OLDRIZZI L, TESSITORE N, D'ANGELO A, VALVO E,
LuPo A, LOSCHIAVO C, FARRIS A, GAMMARO L, RUGIU C,
PANZETrA G: Effects of dietary protein and phosphorus restriction
on the progression of early renal failure, Kidney mt 22:371—376,
1982
63. OLDRIZZI L, RUGIU C, VALVO E, Luo A, L0ScHIAv0 C, GAM-
MARO L, TEssIToIt N, FABRIS A, PANZETTA G, MASCHIO G:
Progression of renal failure in patients with renal disease of diverse
etiology on protein-restricted diet. Kidney mt 27:553—557, 1985
64. EL NAHAS AM, MASTERS-THOMAS A, BRADY SA, FARRINGTON K,
WILKINSON V, HILSON MW, VARGHESE Z, MOORHEAD JF: Selec-
tive effect of low protein diets in chronic renal diseases. Br Med J
289:1337—1341, 1984
65. A1-rMAN P0, BUCHT H, LARSSON 0, UDDEBOM G: Protein-
reduced diet in diabetic renal failure. Gun Nephrol 19:217—220, 1983
66. MITCH WE, WALSER M, STEINMAN TI, HILL S. ZEGER S,
TUNGSANGA K: The effect of a keto acid-amino acid supplement to
a restricted diet on the progression of chronic renal failure. N Engi
J Med 311:623—629, 1984
67. ROSMAN JB, MEIJER S, SLUITER WM, TER WEE PM, PIERS-BECHT
TPM, DONKER AJM: Prospective randomized trial of early dietary
protein restriction in chronic renal failure. Lance: 1:1291—1296,
1984
68. ZELLER KR, JACOBSON H, RASKIN P: The effect of dietary protein
modification on renal function in diabetic nephropathy. Preliminary
report of an ongoing study (qbstract). Kidney mt 3 1:225, 1987
69. TAGUMA Y, KITAMOTO Y, FUTAKI G, UDEDA H, NONMA H,
I5HIZAKI M, TAKAHASHI H, SEKINO H, SASAKI Y: Effect of
captopril on heavy proteinuria in azotemic diabetes. N Engi J Med
313:1617—1620, 1985
70. HOMMEL E, PARVING HH, MATHIESEN E, EDSBERG B, NIELSEN
MD, thESE J: Effect of captopril on kidney function in insulin-
dependent diabetic patients with nephropathy. Br Med J 293:
479—480, 1986
71. REAMS GP, BAyER JH: Effect of enalapril in subjects with hyper-
tension associated with moderate to severe renal dysfunction. Arch
Intern Med 146:2145—2148, 1986
72. Docci D, PISTOCCHI E, TURd F, BALDRATI L: Effect of ibopamine
on the progression of chronic renal failure. Clin Nephrol 26:
121—124, 1986
73. GOLDBERG LI: Dopamine receptors and hypertension: physiologic
and pharmacologic implications. Am J Med 77:37—44, 1984
74. OPIE LH, JENNINGS AA: Role of calcium channel blockade in
chronic hypertension following successful management of hyper-
tensive emergency. Am J Med 81 (suppl 6A):35—42, 1986
75. BARSOTTI G, GIANNONI A, MORELLI E, LAZZERI M, VLAMIS I,
BALDI R, GIOVANNETTI S: The decline of renal function slowed by
very low phosphorus intake in chronic renal patients following a
low nitrogen diet. Clin Nephrol 21:54—59, 1984
76. BARRIENTOS A, ARTEAGA J, Roiico JL, ALVAREZ UDE F,
ALCAZAR JM, RUILOPE LM: Role of the control of phosphate in the
progression of chronic renal failure. Miner Electrolyte Metab
7:127—133, 1982
77. Dooo JV, ANDERSON CF, MITCHELL JC, H0LLEY KE,
ILSTRUP DM, FUSTER V, CHESEBRO JH: Membranoprohferative
glomeronephntis: A prospective clinical trial of platelet-inhibitor
therapy. NEnglJMed3lO:142l—1426, 1984
78. ZIMMERMAN SW, MOORTHY AV, DREHER WH, FRIEDMAN A,
VARANASI U: Prospective trial of warfarin and dipyridamole in
patients with inembranoproliferative glomerülonephritis. Am J Med
75:920—927, 1983
79. SCHULTZE RG, WEISSER F, BRICKER NS: The influence of uremia
on fractional sodium reabsorption by the proximal tubule. Kidney
mt 2:59—65, 1972
80. CHAN AYM, CHENG ML, KEIL LC, MYERS BD: Functional
response of diseased glomeruli to a large protein-meal. J Clin
invest, (in press)
81. NEWSON G, SABATINI S, KURTZMAN NA: Renal reserve in normal
subjects, transplant donors and patients with nephrotic syndrome
(abstract). Kidney In: 3 1:211, 1987
82. BIDANI A, SCHWARTZ MM, LEWIS EJ: Renal autoregulation and
glomerular vulnerability to hypertensive injury in the remnant
kidney model. Am J Physiol 252:F1003—FlOlO, 1987
83, PLOTH DW, RoY RN, HUANG W-C, NAVAR LG: Impaired renal
blood flow and cortical pressure autoregulation in contralateral
kidneys of Goldblatt hypertensive rats. Hypertension 3:67—74, 1981
84. KAYSEN GA, ROSENTHAL C, HUTCHISON FN: Urinary albumin
(UalbV) excretion increases in normal rats after increased dietary
protein intake without a change in glomerular permeability to
neutral dextrans (abstract). Gun Res 34:600A, 1986
85. SHEMESH 0, DEEN WM, BRENNER BM, MCNEELY E, MYERS BD:
Effect of colloid volume expansion on glomerular barrier size-
selectivity in humans. Kidney mt 29:916—923, 1986
86. KAYSEN GA, GAMBERTOGLIO J, JIMINEZ 1, JONES H, HUTCHISON
FN: Effect of dietary protein intake on albumin homeostasis in
nephrotic patients. Kidney In: 29:592—577, 1986
87. KIPROV DD, COLVIN RB, MCCLUSKEY RT: Focal and segmental
glomerulosclerosis and proteinuria associated with unilateral renal
agenesis. Lab invest 46:275—281, 1982
88. MITCH WE, COLLIER VU, WALSER M: Creatinine metabolism in
chronic renal failure. Clin Sci 58:327—335, 1980
89. STEER KA, SOCHOR M, MCLEAN P: Renal hypertrophy in experi-
mental diabetes. Changes in pentose phosphate pathway activity.
Diabetes 34:485-490, 1985
90. STEPHAN F, REVILLE P, DE LAHARPE F, KOLL-BACK M. Impair-
ment of renal compensatory hypertrophy by hypothyroidism in the
rat. Life Sci 30:623—631, 1982
91. CHRISTENSEN CK, MOGENSEN CE: Effect of antihypertensive
treatment on progression of disease in incipient diabetic nephrop-
athy. Hypertension 7(11): 109—114, 1985
92. HEEG JE, DE JONG PE, VAN DER HEM GK, DE ZEEUW D:
Reduction of proteinuria by angiotensin converting enzyme inhibi-
tion. Kidney In: 32:78—83, 1987
93. KLEINKNECHT C, LAOUARI D, HINGLAIS N, HABIB R, DODU C,
LACOUR B, BROYER M: Role of amount and nature of carbohy-
drates in the course of experimental renal failure. Kidney Int
30:687—693, 1986
94. SCHWARTZ MM, BIDANI AK, LEwIs EJ: Glomerular epithelial cell
function and pathology following extreme ablation of renal mass.
Am J Pathol 126:315—324, 1987
